.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Fuji
Express Scripts
Johnson and Johnson
Medtronic
AstraZeneca
Cantor Fitzgerald
Federal Trade Commission
Merck
Covington

Generated: December 18, 2017

DrugPatentWatch Database Preview

FAZACLO ODT Drug Profile

« Back to Dashboard

When do Fazaclo Odt patents expire, and when can generic versions of Fazaclo Odt launch?

Fazaclo Odt is a drug marketed by Jazz Pharms Iii and is included in one NDA. There are three patents protecting this drug.

This drug has forty patent family members in nineteen countries.

The generic ingredient in FAZACLO ODT is clozapine. There are thirteen drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the clozapine profile page.
Drug patent expirations by year for FAZACLO ODT

Pharmacology for FAZACLO ODT

Medical Subject Heading (MeSH) Categories for FAZACLO ODT

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Jazz Pharms IiiFAZACLO ODTclozapineTABLET, ORALLY DISINTEGRATING;ORAL021590-004May 30, 2007RXYesNo► Subscribe► SubscribeY► Subscribe
Jazz Pharms IiiFAZACLO ODTclozapineTABLET, ORALLY DISINTEGRATING;ORAL021590-006Jul 9, 2010ABRXYesNo► Subscribe► SubscribeY► Subscribe
Jazz Pharms IiiFAZACLO ODTclozapineTABLET, ORALLY DISINTEGRATING;ORAL021590-003Jun 3, 2005DISCNNoNo► Subscribe► SubscribeY► Subscribe
Jazz Pharms IiiFAZACLO ODTclozapineTABLET, ORALLY DISINTEGRATING;ORAL021590-001Feb 10, 2004ABRXYesNo► Subscribe► SubscribeY► Subscribe
Jazz Pharms IiiFAZACLO ODTclozapineTABLET, ORALLY DISINTEGRATING;ORAL021590-002Feb 10, 2004ABRXYesYes► Subscribe► SubscribeY► Subscribe
Jazz Pharms IiiFAZACLO ODTclozapineTABLET, ORALLY DISINTEGRATING;ORAL021590-003Jun 3, 2005DISCNNoNo► Subscribe► SubscribeY► Subscribe
Jazz Pharms IiiFAZACLO ODTclozapineTABLET, ORALLY DISINTEGRATING;ORAL021590-006Jul 9, 2010ABRXYesNo► Subscribe► SubscribeY► Subscribe
Jazz Pharms IiiFAZACLO ODTclozapineTABLET, ORALLY DISINTEGRATING;ORAL021590-005Jul 9, 2010ABRXYesNo► Subscribe► SubscribeY► Subscribe
Jazz Pharms IiiFAZACLO ODTclozapineTABLET, ORALLY DISINTEGRATING;ORAL021590-004May 30, 2007RXYesNo► Subscribe► SubscribeY► Subscribe
Jazz Pharms IiiFAZACLO ODTclozapineTABLET, ORALLY DISINTEGRATING;ORAL021590-004May 30, 2007RXYesNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: FAZACLO ODT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Jazz Pharms IiiFAZACLO ODTclozapineTABLET, ORALLY DISINTEGRATING;ORAL021590-005Jul 9, 2010► Subscribe► Subscribe
Jazz Pharms IiiFAZACLO ODTclozapineTABLET, ORALLY DISINTEGRATING;ORAL021590-003Jun 3, 2005► Subscribe► Subscribe
Jazz Pharms IiiFAZACLO ODTclozapineTABLET, ORALLY DISINTEGRATING;ORAL021590-004May 30, 2007► Subscribe► Subscribe
Jazz Pharms IiiFAZACLO ODTclozapineTABLET, ORALLY DISINTEGRATING;ORAL021590-002Feb 10, 2004► Subscribe► Subscribe
Jazz Pharms IiiFAZACLO ODTclozapineTABLET, ORALLY DISINTEGRATING;ORAL021590-002Feb 10, 2004► Subscribe► Subscribe
Jazz Pharms IiiFAZACLO ODTclozapineTABLET, ORALLY DISINTEGRATING;ORAL021590-001Feb 10, 2004► Subscribe► Subscribe
Jazz Pharms IiiFAZACLO ODTclozapineTABLET, ORALLY DISINTEGRATING;ORAL021590-006Jul 9, 2010► Subscribe► Subscribe
Jazz Pharms IiiFAZACLO ODTclozapineTABLET, ORALLY DISINTEGRATING;ORAL021590-003Jun 3, 2005► Subscribe► Subscribe
Jazz Pharms IiiFAZACLO ODTclozapineTABLET, ORALLY DISINTEGRATING;ORAL021590-004May 30, 2007► Subscribe► Subscribe
Jazz Pharms IiiFAZACLO ODTclozapineTABLET, ORALLY DISINTEGRATING;ORAL021590-001Feb 10, 2004► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: FAZACLO ODT

Country Document Number Estimated Expiration
Spain2167921► Subscribe
Japan2008001726► Subscribe
Japan5072513► Subscribe
Hungary229152► Subscribe
China1264299► Subscribe
Japan3190299► Subscribe
Turkey200000139► Subscribe
New Zealand502228► Subscribe
Canada2284663► Subscribe
Spain2525720► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Argus Health
US Army
US Department of Justice
Fuji
Covington
Julphar
Federal Trade Commission
Baxter
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot